We have another new acne treatment for you this week!
Click here and scroll down for previous newsletters.
1. Pictured Counselling Cue Card: a free sample of our counselling reference
2. Patient Consultation: exactly what a pharmacist may say to a patient picking up this medication, with formatting to show where the information is coming from on the cue card
Clearly, there are nuances that may not be captured in this format. The goal here is to provide you with an example of how a pharmacist may counsel a patient. Basic counselling tactics (e.g. showing the patient the labeled medication as you read it, having the patient repeat the information in their own words, double checking allergies, and so on) may not be depicted in the interest of keeping the content concise.
RPh: Hi! Is this medication new for you?
Patient: Yes.
RPh: Ok. What has (prescriber) told you?
Patient: They said it's for my acne.
RPh: Ok. This medication is a called CLASCOTERONE, and you'll use it (as directed). It's in the family of what's called a topical androgen receptor inhibitor, but basically it will help with the acne. Acne may worsen at first, but after 2-3 months you should notice a significant difference. Side effects may include skin dryness, irritation, and redness; please let us or your (prescriber) know if these become bothersome, as usually using it less often or for shorter periods can help get your skin accustomed to the product and avoid side-effects. Apply to all affected areas, not only where you currently have acne which would otherwise possibly develop in the future. This medication may not be right for you if you have high potassium levels or have trouble with infrequent periods. Stored at room temperature it lasts 6 months once you pick it up from your pharmacy.
RPh: Did you have any questions?
Patient: Can I breastfeed while using it?
RPh: It's a fairly new medication, so there is little experience with it in pregnant individuals, however as long as your baby does not come into contact with it directly then it should be considered safe.
We hope you have found this useful, and please reply to this email with any feedback or topic suggestions you can. It will be the key to making this newsletter the best it can be.
Comments